{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1"},{"groupId":"OG002","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"The duration of response is the time from initiation of first response to first documentation of disease progression or death. Patients who have not progressed will be censored at the date of their last disease evaluation.","groups":[{"description":"Ibrutinib 560 mg on Days 1-28,\\> Lenalidomide 15 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\\>\n\n\\> Every 28 days","id":"OG000","title":"Dose Level 1 (Starting DL)"},{"description":"Ibrutinib 560 mg on Days 1-28,\\> Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\\>\n\n\\> Every 28 days","id":"OG001","title":"Dose Level 2"},{"description":"Ibrutinib 840 mg on Days 1-28,\\> Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\\>\n\n\\> Every 28 days","id":"OG002","title":"Dose Level 3"}],"paramType":"NUMBER","populationDescription":"All eligible patients who met IMWG criteria for CR, VGPR, or PR on two consecutive evaluations at least 4 weeks apart","reportingStatus":"POSTED","timeFrame":"34 Months","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}